Immunomodulatory Therapies for COVID-19 Management

Immunomodulatory therapies for COVID-19 aim to recalibrate the host immune response, attenuating excessive inflammation while preserving antiviral defence. Severe COVID-19 is characterised by dysregulated cytokine production, widespread endothelial activation and immune cell exhaustion, culminating in acute respiratory distress syndrome and multisystem injury. Core strategies include corticosteroids to suppress broad inflammatory cascades; monoclonal antibodies against interleukins or their receptors, notably interleukin-6 (IL-6) antagonists; small-molecule inhibitors of intracellular signalling pathways such as Janus kinase (JAK) inhibitors; passive immunotherapies encompassing convalescent plasma and pooled intravenous immunoglobulins (IVIG); and emerging cell-based approaches, for example mesenchymal stromal cells, to foster tissue repair and immune homeostasis. Optimisation of dose, timing and patient selection has been pivotal in translating these interventions into reduced mortality and shorter hospital stays. The global diversity of healthcare settings has driven adaptations of immunomodulatory regimens to resource availability, while ongoing surveillance of viral variants and host immune phenotypes informs personalised application. Collectively, these therapies exemplify a precision-medicine approach to mitigate life-threatening inflammation without compromising viral clearance.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Immunomodulatory Therapies for COVID-19 Management publication trend

The graph below shows the total number of articles in immunomodulatory therapies for covid-19 management across all publications each year (not limited to Nature Index journals).

Technical terms

Immunomodulatory therapy: Treatment designed to modify the immune system’s activity, either by enhancing antiviral responses or by suppressing harmful inflammation.

Intravenous immunoglobulin (IVIG): A preparation of pooled antibodies administered intravenously to neutralise pathogens and regulate immune functions.

Cytokine storm: An excessive and dysregulated release of pro-inflammatory cytokines leading to tissue damage and organ dysfunction.

Interleukin-6 receptor antagonist: A monoclonal antibody that blocks IL-6 signalling, thereby reducing inflammation.

Janus kinase (JAK) inhibitor: A small molecule that interferes with intracellular signalling pathways activated by cytokine receptors.

Convalescent plasma: Plasma collected from recovered individuals containing neutralising antibodies against the pathogen.

Glucocorticoids: Steroid hormones used at pharmacological doses to suppress multiple inflammatory pathways.

References

1. Hypothesis for potential pathogenesis of SARS-CoV-2 infection–a review of immune changes in patients with viral pneumonia. Emerging Microbes & Infections (2020).
2. Clinical efficacy of intravenous immunoglobulin therapy in critical ill patients with COVID‐19: a multicenter retrospective cohort study. Clinical & Translational Immunology (2020).
3. The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial. BMC Infectious Diseases (2020).
4. Adjunct Immunotherapies for the Management of Severely Ill COVID-19 Patients. Cell Reports Medicine (2020).